Back to top
more

Akebia Therapeutics (AKBA)

(Delayed Data from NSDQ)

$3.76 USD

3.76
2,529,426

+0.04 (1.08%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $3.76 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -21.21% and 23.61%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Are Options Traders Betting on a Big Move in Akebia (AKBA) Stock?

by Zacks Equity Research

Investors need to pay close attention to Akebia (AKBA) stock based on the movements in the options market lately.

Zacks Equity Research

Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -6.25% and -2.66%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Akebia Therapeutics (AKBA) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -70.00% and -11.93%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Implied Volatility Surging for Akebia Therapeutics (AKBA) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately.

Zacks Equity Research

New Strong Sell Stocks for May 12th

by Zacks Equity Research

AKBA, CNA, EBMT, FCEL, and HMPT have been added to the Zacks Rank #5 (Strong Sell) List on May 12, 2021

Zacks Equity Research

Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -36.36% and 19.43%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Akebia (AKBA) Files NDA for Vadadustat for Anemia Due to CKD

by Zacks Equity Research

Akebia (AKBA) submits new drug application for vadadustat to treat anemia due to chronic kidney disease in adult patients who are on dialysis as well as who are not on dialysis.

Zacks Equity Research

Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Implied Volatility Surging for Akebia Therapeutics (AKBA) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately.

Zacks Equity Research

Is the Options Market Predicting a Spike in Akebia (AKBA) Stock?

by Zacks Equity Research

Investors need to pay close attention to Akebia (AKBA) stock based on the movements in the options market lately.

Zacks Equity Research

Akebia Therapeutics (AKBA) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -82.61% and -21.20%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Akebia Therapeutics (AKBA) Looks Good: Stock Adds 6.7% in Session

by Zacks Equity Research

Akebia Therapeutics (AKBA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Zacks Equity Research

Do Options Traders Know Something About Akebia (AKBA) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Akebia (AKBA) stock based on the movements in the options market lately.

Zacks Equity Research

Biotech Stock Roundup: GILD Submits BLA, ALBO Gains on Study Data & More

by Zacks Equity Research

The biotech sector remains in focus with regulatory and other pipeline updates.

Zacks Equity Research

Akebia Falls as Vadadustat Fails to Meet Safety Endpoint

by Zacks Equity Research

Akebia (AKBA) posts top-line data from two phase III studies, namely PRO2TECT, which are evaluating vadadustat for treating anemia due to chronic kidney disease in adults not on dialysis. Shares down.

Zacks Equity Research

Implied Volatility Surging for Akebia (AKBA) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Akebia (AKBA) stock based on the movements in the options market lately.

Zacks Equity Research

Akebia Therapeutics (AKBA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 4.35% and 18.24%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Encompass Health Continues to Strengthen Presence in Florida

by Zacks Equity Research

Encompass Health (EHC) intends to offer improved health outcomes through plans to construct a new hospital in Florida, where it already boasts of a strong base.

Zacks Equity Research

Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (AKBA) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Akebia Therapeutics (AKBA) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Akebia Therapeutics (AKBA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Akebia Therapeutics, Inc. (AKBA) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Akebia Therapeutics, Inc. (AKBA).